| Product Name |
Recombinant Human Interferon Inducible 35 (IFI35) Protein |
| Product Overview |
This recombinant human Interferon Inducible 35 (IFI35) protein includes amino acids 2-286aa of the target gene is expressed in E.coli.The protein is supplied in liquid or lyophilized powder form and formulated in PBSprior to lyophilization. |
| Target Uniprot Id |
P80217 |
| Recommended Name |
Interferon-induced 35 kDa protein |
| Gene Name |
IFI35 |
| Synonyms |
IFP35 |
| Species |
Human |
| Predicted Molecular Mass |
38 kDa |
| Expression System |
E.coli |
| Expression Range |
2-286aa |
| Tag |
N-6His |
| Purity |
>95% |
| Formulation |
Liquid or Lyophilized powder |
| Buffer |
PBS |
| Storage Condition |
1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
| Reconstitution Instruction |
Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
| Applications |
Positive Control; Immunogen; SDS-PAGE; WB |
| Research Area |
Cell Biology |
| Target Function |
Acts as a signaling pathway regulator involved in innate immune system response. In response to interferon IFN-alpha, associates in a complex with signaling pathway regulator NMI to regulate immune response; the complex formation prevents proteasome-mediated degradation of IFI35 and correlates with IFI35 dephosphorylation. In complex with NMI, inhibits virus-triggered type I interferon/IFN-beta production. In complex with NMI, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of the NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries. Beside its role as an intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns (DAMPs) to promote inflammation when actively released by macrophage to the extracellular space during cell injury and pathogen invasion. Macrophage-secreted IFI35 activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4/TLR4 activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of proinflammatory cytokines. |
| Subcellular Location |
Cytoplasm. Nucleus. Secreted. |
| Protein Family |
NMI family |
| Tissue Specificity |
Expressed in a wide range of cell types, including fibroblasts, macrophages, and epithelial cells. |
